Genfit shares soar 26% in a week, among the leaders of the SBF 120
The Lille-based biotech specialising in liver and metabolic diseases accelerates sharply in late afternoon trading, in a Paris market that is stagnating. The move extends a rebound begun at the end of October, after a very difficult quarter, and comes two days before a quarterly publication.
A rebound that places Genfit above its three moving averages
Genfit shares gain 6.35% to €11.06 while the CAC 40 and the SBF 120 are virtually unchanged, placing it among the strongest gainers of the SBF 120.
Over the week, the gain reaches 26.26%. This recovery has not yet erased the quarterly decline of -24.56%, but it reduces the loss accumulated since the summer.
The stock has risen back above its MM50 (€10.80, a gap of +2.41%) and its MM200 (€9.98, a gap of +10.82%), which it had lost during the October correction. The gap with the MM20 (€9.25) reaches +19.57%, a sign of a recent acceleration rather than a simple return to balance.
The €11.46 resistance level in sight ahead of third-quarter sales
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The share price is now about 3.6% below the €11.46 resistance, the nearest level on the chart. The RSI, at 59, remains far from overbought zones: the rebound has therefore not yet exhausted its momentum.
On November 2, on the sidelines of the AASLD congress, Genfit also detailed its strategy in acute-on-chronic liver failure and its MASH diagnostic activity, through a scientific and strategic programme presented without any new figures. The company will publish its third-quarter revenue on November 5.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
